Veracyte, Inc. (VCYT) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-26

Business type: Treadmill

How it makes money

It generates revenue by performing genomic tests in proprietary labs and selling test kits to international hospitals, primarily for prostate and thyroid cancers.

The company serves global markets with two complementary models: performing Laboratory Developed Tests (LDTs) in centralized U.S. labs and selling In Vitro Diagnostic (IVD) kits abroad. In the U.S. market, clinicians send samples to the company’s CLIA-certified laboratories, where it processes tests and bills payers directly using specific CPT codes.

International revenue is driven by selling Prosigna breast cancer kits directly to laboratories and hospitals. Profitability depends on test volume and the successful negotiation of reimbursement rates with a mix of commercial insurers and government payers like Medicare, which represents over 50% of testing revenue through Fee-For-Service and Medicare Advantage plans.

What protects it: the moat

It defends its market position by being the only gene expression test in the NCCN risk stratification table for clinically localized prostate cancer.

The company’s competitive advantage is built on an evidence-generation engine that has produced over 115 peer-reviewed studies for Decipher and 160 for Afirma. This validation is critical for securing inclusion in the NCCN Clinical Practice Guidelines, which in turn facilitates broad coverage by payers representing over 275 million enrollees.

Management claims that its growing repository of genomic data and specialized AI capabilities create a high barrier to entry. These tools enable the detection of pathology features and genomic variants that traditional clinical parameters, such as PSA levels or basic cytopathology, often fail to identify.

What growth costs

It invests in whole-genome capabilities through the C2i Acquisition while managing a $377.6 million accumulated deficit from its historical diagnostic development.

Reinvestment is primarily directed toward clinical evidence studies to drive physician adoption and regulatory approvals for new products like TrueMRD and the Percepta Nasal Swab. The company must also fund the integration of acquired assets, such as the C2i MRD platform, to expand its role from initial diagnosis into long-term patient monitoring and disease recurrence detection.

While it reported a net income of $66.4 million in 2025, it structurally requires continuous spending on research and development to transition its pipeline from research stages to commercially reimbursed tests. It also spends to adapt its U.S. laboratory tests into decentralized IVD formats for global distribution on platforms like Illumina's NextSeq.

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Other companies in Diagnostics & Research